Isothermal Nucleic Acid Amplification Technology Market Growth Report, 2030

NEW YORK - July 3, 2024 - PRLog -- The global isothermal nucleic acid amplification technology market generated revenue of USD 4,425.5 million in 2023 and is expected to witness a CAGR of 9.4% during 2024–2030, reaching USD 8,159.4 million by 2030. This growth is attributed to the significant increase in its usage as a molecular testing technique due to the rising prevalence of infectious diseases, including tuberculosis, hepatitis, and influenza, which are among the leading causes of death, particularly in developing countries.

Tuberculosis, hepatitis, and flu are diseases transmitted by way of infectious diseases in which the leading cause of death is mostly observed in underdeveloped countries.
a bewildering range of diagnostic tests combined with an increasing number of Emergency Use Authorizations for CLIA-waived tests are spurring the development of the isothermal nucleic acid amplification technology market. These tests being free of complex procedures, lesser chances of error, and being able to personalize the dose on patients are a few instances of why these tests remain so popular.

These technologies have various uses such as gene manipulation that is done with recombinant DNA and similar molecular biology practices. It is a new way to detect prepare and analyze a small number of nucleic acids containing DNA or RNA that enter into cells.

Historically, there has never been a life history that was free from infectious diseases and this has continued to be a major cause of death and disability. With the increasing incidences of communicable diseases around the world which as weighty factors in the market expansion, this field is seeing major growth nowadays.

Browse detailed report analysis on Isothermal Nucleic Acid Amplification Technology Industry Research Report, 2030 (https://www.psmarketresearch.com/market-analysis/isotherm...)

Key Insights

• In 2023, the consumables category led the isothermal nucleic acid amplification technology industry, with a 70% revenue share, projected to uphold supremacy.
• The wide use of reagents in diagnostic laboratories and major healthcare settings contributes to this supremacy.
• Obtainability of polymerases with high strand displacement abilities further boosts demand for consumables.
• In 2023, the hospital's category led with a 60% share in the INAAT industry, projected to uphold supremacy because of the augmented usage of miniaturized POC instruments.
• Increased throughput and automation capabilities of INAAT technologies for processing large sample volumes are expected to drive segment growth.
• North America held around 45% of the market in 2023, poised for robust growth due to established research infrastructure and demand for nucleic-acid-amplification-based diagnostics.
• It has a potential for testing all RNA and DNA sequences at the same time and is capable of detecting both Zika and SARS-CoV-2 viruses in human specimens.